The Pharma Data
DECEMBER 16, 2020
Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
XTalks
DECEMBER 13, 2023
This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 27, 2021
Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest.
The Pharma Data
SEPTEMBER 1, 2020
Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Presentation Topic: Biomarkers and Bioinformatics. Certain foods that may contain very high amounts of tyramine could cause severe hypertension in patients taking ZEPOSIA. Author: Zhang.
Drug Discovery World
NOVEMBER 30, 2023
This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.
Drug Discovery World
NOVEMBER 15, 2022
Gene-to-antibody production begins with scientists entering antibody sequences as starting material, after which bioinformatics tools filter out potentially non-viable sequences. The libraries contain only the sequences that occur in the human repertoire, rather than randomly generated sequences,” adds Dr Leproust. .
Drug Discovery World
JULY 29, 2022
Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate the molecular interactions of the p53 protein known to give protection against cancers.
Expert insights. Personalized for you.
40 
Let's personalize your content